针对癌症患者体内人髓源性抑制细胞的临床证据。
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.
作者信息
Tobin Richard P, Davis Dana, Jordan Kimberly R, McCarter Martin D
机构信息
Department of Surgery, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA; and.
Department of Immunology and Microbiology, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA.
出版信息
J Leukoc Biol. 2017 Aug;102(2):381-391. doi: 10.1189/jlb.5VMR1016-449R. Epub 2017 Feb 8.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that represent a formidable obstacle to the successful treatment of cancer. Patients with high frequencies of MDSCs have significantly decreased progression-free survival (PFS) and overall survival (OS). Whereas there is experimental evidence that the reduction of the number and/or suppressive function of MDSCs in mice improves the efficacy of anti-cancer therapies, there is notably less evidence for this therapeutic strategy in human clinical trials. Here, we discuss currently available data concerning MDSCs from human clinical trials and explore the evidence that targeting MDSCs may improve the efficacy of cancer therapies.
摘要
髓系来源的抑制细胞（MDSCs）是一群异质性的未成熟髓细胞，是癌症成功治疗的巨大障碍。MDSCs频率高的患者无进展生存期（PFS）和总生存期（OS）显著降低。虽然有实验证据表明，减少小鼠体内MDSCs的数量和/或抑制功能可提高抗癌治疗的疗效，但在人类临床试验中，这一治疗策略的证据明显较少。在此，我们讨论目前来自人类临床试验的有关MDSCs的可用数据，并探讨靶向MDSCs可能提高癌症治疗疗效的证据。
相似文献
1
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.
J Leukoc Biol. 2017 Aug;102(2):381-391. doi: 10.1189/jlb.5VMR1016-449R. Epub 2017 Feb 8.
2
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
Front Immunol. 2020 Jul 30;11:1680. doi: 10.3389/fimmu.2020.01680. eCollection 2020.
3
Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Front Immunol. 2021 Feb 4;11:585214. doi: 10.3389/fimmu.2020.585214. eCollection 2020.
4
Suppression of T cells by myeloid-derived suppressor cells in cancer.
Hum Immunol. 2017 Feb;78(2):113-119. doi: 10.1016/j.humimm.2016.12.001. Epub 2016 Dec 7.
5
Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
Mol Immunol. 2020 Jan;117:201-215. doi: 10.1016/j.molimm.2019.11.014. Epub 2019 Dec 10.
6
Targeting myeloid-derived suppressor cells for cancer immunotherapy.
Cancer Immunol Immunother. 2018 Aug;67(8):1181-1195. doi: 10.1007/s00262-018-2175-3. Epub 2018 May 31.
7
Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.
Cancer Immunol Immunother. 2017 Aug;66(8):989-996. doi: 10.1007/s00262-017-1963-5. Epub 2017 Feb 21.
8
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Signal Transduct Target Ther. 2021 Oct 7;6(1):362. doi: 10.1038/s41392-021-00670-9.
9
Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
Cancer Immunol Immunother. 2017 Apr;66(4):503-513. doi: 10.1007/s00262-016-1953-z. Epub 2017 Jan 20.
10
Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.
Oncotarget. 2016 Aug 9;7(32):51840-51853. doi: 10.18632/oncotarget.10123.
引用本文的文献
1
Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update.
Ther Adv Med Oncol. 2025 Jun 25;17:17588359251349321. doi: 10.1177/17588359251349321. eCollection 2025.
2
Taurohyocholic acid acts as a potential predictor of the efficacy of tyrosine kinase inhibitors combined with programmed cell death-1 inhibitors in hepatocellular carcinoma.
Front Pharmacol. 2024 Feb 23;15:1364924. doi: 10.3389/fphar.2024.1364924. eCollection 2024.
3
MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade.
Cell Death Dis. 2024 Mar 8;15(3):198. doi: 10.1038/s41419-024-06524-w.
4
Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products.
Arch Immunol Ther Exp (Warsz). 2023 Jul 6;71(1):17. doi: 10.1007/s00005-023-00681-0.
5
Effect of crosstalk among conspirators in tumor microenvironment on niche metastasis of gastric cancer.
Am J Cancer Res. 2022 Dec 15;12(12):5375-5402. eCollection 2022.
6
Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach.
Cancers (Basel). 2022 Nov 15;14(22):5605. doi: 10.3390/cancers14225605.
7
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.
Clin Cancer Res. 2023 Apr 3;29(7):1209-1219. doi: 10.1158/1078-0432.CCR-22-2495.
8
"The Two Sides of the Same Coin"-Medical Cannabis, Cannabinoids and Immunity: Pros and Cons Explained.
Pharmaceutics. 2022 Feb 10;14(2):389. doi: 10.3390/pharmaceutics14020389.
9
Myeloid cells in COVID-19 microenvironment.
Signal Transduct Target Ther. 2021 Oct 27;6(1):372. doi: 10.1038/s41392-021-00792-0.
10
Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets.
Cancer Immunol Res. 2021 Dec;9(12):1400-1412. doi: 10.1158/2326-6066.CIR-21-0232. Epub 2021 Sep 22.
本文引用的文献
1
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.
Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150.
2
Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Clin Cancer Res. 2016 Dec 1;22(23):5661-5672. doi: 10.1158/1078-0432.CCR-15-3104. Epub 2016 May 13.
3
Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2.
J Immunol. 2016 Apr 15;196(8):3470-8. doi: 10.4049/jimmunol.1501785. Epub 2016 Mar 2.
4
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Trends Immunol. 2016 Mar;37(3):208-220. doi: 10.1016/j.it.2016.01.004. Epub 2016 Feb 6.
5
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.
Oncotarget. 2016 Mar 8;7(10):11137-50. doi: 10.18632/oncotarget.7097.
6
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
7
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Clin Cancer Res. 2015 Sep 15;21(18):4073-4085. doi: 10.1158/1078-0432.CCR-14-2742. Epub 2015 Apr 28.
8
A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992-2010.
BMC Cancer. 2015 Mar 27;15:185. doi: 10.1186/s12885-015-1188-y.
9
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31.
10
Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer.
J Transl Med. 2015 Feb 1;13:47. doi: 10.1186/s12967-015-0410-7.
Zotero 插件